{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:31Z","timestamp":1792788091862,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014418","name":"Harbin Medical University Cancer Hospital","doi-asserted-by":"publisher","award":["JJQN2023-16"],"award-info":[{"award-number":["JJQN2023-16"]}],"id":[{"id":"10.13039\/100014418","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Analytical Biochemistry"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ab.2026.116267","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:49:27Z","timestamp":1791269367000},"page":"116267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Determination of 5-Fluorouracil, 5,6-dihydro-5-Fluorouracil, Uracil and Dihydrouracil by UPLC-MS\/MS in plasma and its application in hepatocellular carcinoma"],"prefix":"10.1016","volume":"720","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2759-7818","authenticated-orcid":false,"given":"Zhiqiang","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ab.2026.116267_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1568011023354146","article-title":"The prodrugs of 5-fluorouracil","volume":"2","author":"Malet-Martino","year":"2002","journal-title":"Curr Med Chem Anticancer Agents"},{"issue":"3","key":"10.1016\/j.ab.2026.116267_bib2","first-page":"532","article-title":"Guideline for the diagnosis and treatment of primary hepatocellular carcinoma (2024 edition)","volume":"15","year":"2024","journal-title":"Medical Journal of Peking Union Medical College Hospital"},{"issue":"5","key":"10.1016\/j.ab.2026.116267_bib3","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1)","volume":"40","author":"Lyu","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ab.2026.116267_bib4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ab.2026.116267_bib5","first-page":"671","article-title":"Research progress on cardiotoxicity of 5-fluorouracil and prevention with traditional Chinese medicine","volume":"38","author":"Xu","year":"2021","journal-title":"Tianjin Journal of Traditional Chinese Medicine"},{"issue":"1","key":"10.1016\/j.ab.2026.116267_bib6","article-title":"Individualization of 5-Fluorouracil in the treatment of colorectal cancer","volume":"2010","author":"Alnaim","year":"2010","journal-title":"SRX Pharmacology"},{"issue":"5","key":"10.1016\/j.ab.2026.116267_bib7","first-page":"582","article-title":"Correlation between steady-state plasma concentration of 5-fluorouracil and individual pharmacological differences and toxicity in the FOLFOX6 regimen","volume":"42","author":"Zhang","year":"2017","journal-title":"J. Bengbu Med. Coll."},{"issue":"40","key":"10.1016\/j.ab.2026.116267_bib8","first-page":"3838","article-title":"Research progress on dose selection of 5-fluorouracil","volume":"24","author":"Yang","year":"2013","journal-title":"China Pharm."},{"issue":"3","key":"10.1016\/j.ab.2026.116267_bib9","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/cpt.1124","article-title":"Therapeutic drug monitoring in oncology:IATDMCT recommendations for 5-fluorouracil therapy","volume":"105","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.ab.2026.116267_bib10","first-page":"1364","article-title":"Research progress on resistance mechanisms and new therapeutic strategies of 5-fluorouracil in the treatment of colon cancer","volume":"46","author":"Li","year":"2025","journal-title":"International Journal of Laboratory Medicine"},{"issue":"4","key":"10.1016\/j.ab.2026.116267_bib11","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage","volume":"17","author":"Gamelin","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.ab.2026.116267_bib12","first-page":"1476","article-title":"Clinical significance of detecting 5-FU plasma concentration in colorectal cancer patients by high-performance liquid chromatography","volume":"17","author":"Dong","year":"2010","journal-title":"Chin. J. Cancer Prev. Treat."},{"issue":"1","key":"10.1016\/j.ab.2026.116267_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/bmc.2741","article-title":"LC-MS\/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients","volume":"27","author":"B\u00fcchel","year":"2013","journal-title":"Biomed. Chromatogr."},{"issue":"8","key":"10.1016\/j.ab.2026.116267_bib14","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1515\/cclm-2012-0641","article-title":"Comparative evaluation of the My5-FU\u2122 immunoassay and LC-MS\/MS in monitoring the 5-fluorouracil plasma levels in cancer patients","volume":"51","author":"B\u00fcchel","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.ab.2026.116267_bib15","series-title":"ICH M10: Bioanalytical Method Validation and Study Sample Analysis","year":"2022"},{"key":"10.1016\/j.ab.2026.116267_bib16","series-title":"Pharmacopoeia of the People's Republic of China: Volume IV[S]","first-page":"466","year":"2020"},{"key":"10.1016\/j.ab.2026.116267_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpba.2016.04.039","article-title":"Development and validation of a rapid and sensitive UPLC-MS\/MS method for determination of uracil and dihydrouracil in human plasma","volume":"126","author":"Jacobs","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"5","key":"10.1016\/j.ab.2026.116267_bib18","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1515\/cclm-2021-0921","article-title":"Pre-analytical considerations for the analysis of uracil and 5,6-dihydrouracil in heparin plasma","volume":"60","author":"Capiau","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"issue":"4","key":"10.1016\/j.ab.2026.116267_bib19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/FTD.0000000000000768","article-title":"Phenotyping of uracil and 5-Fluorouracil metabolism using LC-MS\/MS for prevention of toxicity and dose adjustment of fluoropyrimidines","volume":"42","author":"Tafzi","year":"2020","journal-title":"Ther. Drug Monit."},{"issue":"13","key":"10.1016\/j.ab.2026.116267_bib20","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2217\/pgs.14.126","article-title":"Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio","volume":"15","author":"Sistonen","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"13","key":"10.1016\/j.ab.2026.116267_bib21","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ab.2026.116267_bib22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1634\/theoncologist.2011-0357","article-title":"Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6","volume":"17","author":"Kaldate","year":"2012","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.ab.2026.116267_bib23","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1634\/theoncologist.2014-0132","article-title":"A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy","volume":"19","author":"Patel","year":"2014","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ab.2026.116267_bib24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.ab.2026.116267_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","article-title":"Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis","volume":"34","author":"Deenen","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ab.2026.116267_bib26","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ab.2026.116267_bib27","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/bjc.2017.94","article-title":"Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity","volume":"116","author":"Meulendijks","year":"2017","journal-title":"Br. J. Cancer"}],"container-title":["Analytical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000326972600223X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000326972600223X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:20:23Z","timestamp":1792786823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000326972600223X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":27,"alternative-id":["S000326972600223X"],"URL":"https:\/\/doi.org\/10.1016\/j.ab.2026.116267","relation":{},"ISSN":["0003-2697"],"issn-type":[{"value":"0003-2697","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of 5-Fluorouracil, 5,6-dihydro-5-Fluorouracil, Uracil and Dihydrouracil by UPLC-MS\/MS in plasma and its application in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Analytical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ab.2026.116267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116267"}}